Calidi Biotherapeutics, Inc. (CLDWW)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Gross Profit TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income TTM

-30M -20M -10M 0 10M 20M 30M Q3 '24: -27.6M Q4 '24: -21.8M Q1 '25: -20.1M Q2 '25: -20M Q3 '25: -19.8M Q4 '25: -20.2M Q1 '26: -19.4M Q2 '26: -17.9M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Net Income TTM

-27M -18M -9M 0 9M 18M 27M Q3 '24: -26.3M Q4 '24: -22.1M Q1 '25: -19.9M Q2 '25: -19.9M Q3 '25: -19.9M Q4 '25: -19.9M Q1 '26: -19M Q2 '26: -17.5M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Cost of Revenue TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow TTM

-24M -16M -8M 0 8M 16M 24M Q3 '24: -19.5M Q4 '24: -19.7M Q1 '25: -23M Q2 '25: -22.4M Q3 '25: -21.7M Q4 '25: -21.3M Q1 '26: -18.3M Q2 '26: -17.8M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Free Cash Flow TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Shares Outstanding Quarterly

0 4M 8M 12M Q1 '24: 3.6K Q2 '24: 444 Q3 '24: 652 Q1 '25: 2.3M Q2 '25: 180K Q3 '25: 4.9K Q1 '26: 10.3M Q2 '26: 1.4M Q1 '24 Q2 '24 Q3 '24 Q1 '25 Q2 '25 Q3 '25 Q1 '26 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-18.00 -12.00 -6.00 0.00 6.00 12.00 18.00 Q2 '23: -10.55 Q3 '23: -11.33 Q4 '23: -17.33 Q2 '23 Q3 '23 Q4 '23

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.